At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 513 enrolled
Drug / intervention
Follitropin Delta (FE 999049) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Controlled, Assessor-blind, Parallel Groups, Multicentre, Multinational Trial Evaluating the Immunogenicity of FE 999049 in Repeated Cycles of Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme
In Brief
A Phase 3 clinical trial evaluating Follitropin Delta (FE 999049) and Follitropin Alfa (GONAL-F) for Infertility. Completed, enrolled 513 participants across 13 sites in 11 countries.
Detailed Summary
This trial investigates the immunogenicity of FE 999049 in repeated cycles.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfertility
CountriesBelgium, Brazil, Canada, Czechia, Denmark, France, Italy, Poland, Russia, Spain, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartMar 2014
Primary CompletionMay 2015
Study CompletionJan 2017
TodayJul 2026
First PostedOct 8, 2013
Enrollment StartMar 26, 2014
Primary CompletionMay 1, 2015
Study CompletionJan 3, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.7 years ago
Interventions
Follitropin Delta (FE 999049)drug
Follitropin Alfa (GONAL-F)drug